Psilocybin for Anorexia Nervosa

"According to the age requirements set out in this study, anyone 18 or older but not yet 65 years old may enroll."

"Psilocybin's safety is based on limited data, as this is a Phase 1 trial. Therefore, it received a score of 1 from our team at Power."

"The primary outcome of this clinical trial, which will be measured over a 1 week post final psilocybin session time frame is to Change in health related quality of life as assessed by the Eating disorder Quality of Life Scale (EDQLS). Secondary outcomes include Change in Body mass index (BMI) which is defined as This is a measure of body mass calculated from height and weight (Kg/m^2)., Change in Eating Disorder Examination Questionnaire (EDE-Q) score which is defined as This is a 28-item self-report score that measures severity of eating disorder symptoms across four domains that each"

"As seen on clinicaltrials.gov, this particular study is not currently looking for new patients to enroll. The trial was first posted on August 26th, 2019 and updated most recently on August 19th, 2022. Although this study isn't recruiting now, there are 116 other active trials that might be a match for potential participants."

"0 Psilocybin clinical trials are in Phase 3, with 37 total active Psilocybin clinical trials. Most of these studies are based out of Vancouver, Washington, but there are 40 research sites in total."

"This particular study is no longer recruiting patients. It was initially posted on August 8th, 2019 but the most recent update occurred on August 19th, 2020. However, there are currently 79 other clinical trials related to anorexia nervosa and 37 involving psilocybin that are actively looking for participants."

"The applicants for this trial must suffer from anorexia nervosa and be ages 18-65. Around 18 people will be accepted into the study."